Slide background

C3P3® mRNA production system

High-yield high-performance fully mature and functional mRNA

The C3P3 Expression System produces in only one step large quantities of completely capped, poly(A)-tailed mRNA that is suitable for transfection or electroporation, microinjection or in vitro translation.

The C3P3® mRNA Production System overcomes many of the limitations of traditional co-transcriptional capping methods including incomplete capping, incorrect cap orientation, and the inability to produce cap 1 structures. It results in higher translational efficiency of mRNA with either a cap 0 or cap 1 structure.


A new and disruptive method, overcoming the limitations of current methods and available technologies

Previously, the in vitro production of mRNA was limited in yield and translational activity by the co-transcriptional capping method using cap analog.The presence of dinucleotide cap analog in the transcription reaction mix greatly decreases the mRNA yields and inhibits translation when non-incorporated dinucleotide analogs are not carefully removed. Instead of using a costly and inefficiently incorporated nucleotide cap analog, the C3P3® mRNA Production System uses a virus-derived capping enzyme physically coupled to the RNA polymerase to add the cap at high efficiency capping – versus 80% for other systems using standard m7GpppG cap analog or anti-reverse cap analog (ARCA) and 100% proper cap orientation. The standard cap analog (m7GpppG) used in co-transcriptional reactions can be incorporated in the reverse orientation (33-50% of the time) which is not translated in the cell, thereby decreasing the amount of protein produced per microgram of transfected mRNA.

Simultaneously, the capped mRNA transcripts produced with the C3P3® mRNA Production System are poly(A)-tailed to produce stable, highly functional mRNA transcripts.

cap 1 and cap 2 structures can be produced by further generations to come of the C3P3® enzyme.


The C3P3® mRNA Production System has many uses in regenerative medicine

  • Human vaccines against cancers and infectious diseases
  • Gene and cell therapies
  • Cell reprogramming (generation and manipulation of stem cells)
  • Cell, tissue or organ transplantation or repair; tissue or organ engineering